Skip to main content
. 2022 May 9;2022:4169150. doi: 10.1155/2022/4169150

Figure 5.

Figure 5

Chemosensitivity analysis of in HCC patients with high- or low- expression of SNHG1 or SNHG3. The estimated IC50 for AKT inhibitor VII, bexarotene, bicalutamide, dasatinib, erlotinib, and gefitinib in high- and low- SNHG1 (a) or SNHG3 (b) expression groups. LExp: low-expression; HExp: high-expression. The statistical difference between two groups was compared through the Wilcoxon test. p values were shown in the figure.